Black Friday Sale - Ends Soon!
-35% Off Everything
NVO

Novo Nordisk A/S (NVO)

Last Price$106.50.4%
Market Cap$604.5B
Intrinsic value score
7/10
Great
Intrinsic value
$36.7
DCF value - $0.0 Relative value - $36.7
Overvalued
65.6%
LTM P/E
37.2x
Peer set median: 34.7x
Discount rate
5.0%

NVO Intrinsic value

NVO Intrinsic value overview

Sign up and unlock this exclusive content!
Sign Up for Free

NVO Historical intrinsic value

Sign up and unlock this exclusive content!
Sign Up for Free

NVO Relative value

NVO Valuation multiples overview

Crunching data... Almost there!

NVO vs Peer Set Valuation Multiples Dynamics

Crunching data... Almost there!

NVO DCF sensitivity

Crunching data... Almost there!

NVO Discount rate (WACC)

Crunching data... Almost there!

Discover more NVO fundamentals

Investing armour 2024
50+ visuals to equip yourself with investing wisdom. Sign up to receive it for FREE

FAQ

What is the DCF value of Novo Nordisk A/S (NVO)?

As of today, DCF Value of Novo Nordisk A/S is $0.0, which is undervalued by 0.0%, compared to the current market share price of $106.1

How was the DCF Value calculated?

Step 1: Calculating Intrinsic Enterprise Value DCF Value was calculated by estimating Novo Nordisk A/S future free cash flow and then discounting it, using a chosen discount rate to determine Intrinsic Enterprise Value of $3,321.0B Step 2: Balance Sheet Adjustments Intrinsic Equity Value is calculated by subtracting Balance Sheet items (Cash & Equivalents, Short-term investments and Total Debt) from previously calculated Intrinsic Enterprise Value. This Intrinsic Equity Value is then divided by the total number of outstanding shares of 4,453,746,209 to determine DCF Value of $0.0

What is the Relative value of Novo Nordisk A/S (NVO)?

As of today, Relative Value of Novo Nordisk A/S is $36.7, which is overvalued by 65.4%, compared to the current market share price of $106.1

How was the Relative Value calculated?

Relative Value was calculated by applying various valuation multiples (EV/Revenue, EV/EBITDA, P/E etc.) to Novo Nordisk A/S financials to determine Relative Value of $36.7

What is Novo Nordisk A/S (NVO) discount rate?

Novo Nordisk A/S current Cost of Equity is 5.2%, while its WACC stands at 5.0%. Cost of Equity is used to value equity, while discounting free cash flow to equity holders (such as Net Income or Free Cash Flow to Equity). Weighted Average Cost of Capital (WACC) is used to value the entire firm, while discounting cash flows available to both debt and equity holders (NOPAT or Free Cash Flow to the Firm)

How is Cost of Equity for Novo Nordisk A/S (NVO) calculated?

The Cost of Equity represents the return a company must offer investors to compensate for the risk of investing in its stock. It's calculated using the Capital Asset Pricing Model (CAPM), which combines the risk-free rate, the stock's beta, and the equity risk premium (ERP). This model considers the inherent risk of investing in the stock compared to a risk-free investment and the market's overall risk. Cost of Equity = Risk-Free Rate + Beta x Effective Risk Premium (ERP) 5.2% = 4.51% + 0.1 x 5.0%

How is WACC for Novo Nordisk A/S (NVO) calculated?

WACC, or Weighted Average Cost of Capital, is a calculation that reflects the average rate of return a company is expected to pay its security holders to finance its assets. It is a critical measure in financial analysis for valuing a company’s entire operations. The WACC formula combines the costs of equity and debt, weighted by their respective proportions in the company's capital structure. WACC = Cost of Equity x Equity Weight in Total Capital + Cost of Debt x (1 - Effective Tax Rate) Debt Weight in Total Capital 5.0% = 5.2% x 94.8% + 2.1% x (1 - 16.7%) x 5.2%